Patents by Inventor Anja Fecher
Anja Fecher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8039474Abstract: The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.Type: GrantFiled: December 22, 2005Date of Patent: October 18, 2011Assignee: Actelion Pharmaceutical Ltd.Inventors: Anja Fecher, Heinz Fretz, Markus Riederer
-
Patent number: 7897788Abstract: The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.Type: GrantFiled: March 8, 2005Date of Patent: March 1, 2011Assignee: Actelion Pharmaceutical Ltd.Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
-
Publication number: 20100234396Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.Type: ApplicationFiled: March 16, 2010Publication date: September 16, 2010Applicant: Actelion Pharmaceuticals LtdInventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
-
Patent number: 7727979Abstract: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R?)— or —O— and R? is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence.Type: GrantFiled: March 22, 2004Date of Patent: June 1, 2010Assignee: Actelion Pharmaceuticals Ltd.Inventors: Eva Caroff, Matthias Steger, Oliver Valdenaire, Anja Fecher, Volker Breu, Kurt Hilpert, Heinz Fretz, Thomas Giller
-
Patent number: 7714132Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.Type: GrantFiled: March 7, 2005Date of Patent: May 11, 2010Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
-
Publication number: 20090270414Abstract: The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.Type: ApplicationFiled: December 22, 2005Publication date: October 29, 2009Applicant: Actelion Pharmaceuticals Ltd.Inventors: Anja Fecher, Heinz Fretz, Markus Riederer
-
Patent number: 7544691Abstract: The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinenceType: GrantFiled: September 3, 2004Date of Patent: June 9, 2009Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Volker Breu, Anja Fecher, Heinz Fretz, Thomas Giller, Kurt Hilpert, Olivier Valdenaire
-
Publication number: 20070208004Abstract: The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.Type: ApplicationFiled: March 8, 2005Publication date: September 6, 2007Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
-
Publication number: 20070191416Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.Type: ApplicationFiled: March 7, 2005Publication date: August 16, 2007Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
-
Publication number: 20070123510Abstract: The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinence.Type: ApplicationFiled: September 3, 2004Publication date: May 31, 2007Applicant: ACTELION PHARMACEUTICALS LTD.Inventors: Volker Breu, Anja Fecher, Heinz Fretz, Thomas Giller, Kurt Hilpert, Olivier Valdenaire
-
Patent number: 7214685Abstract: The chemotherapy of malignant tumours is greatly restricted by the generally slight differentiation of the available cytostatic agents between normal and malignant tissue. In order to achieve an improvement of the selectivity in cancer therapy, novel prodrugs have been developed from 6-hydroxy-2,3-dihydro-1H-indolene, 5-hydroxy-1,2-dihydro-3H-pyrrolo[3,2-e]indolene and 5-hydroxy-1,2-dihydro-3H-benzo[e]indolene as well as from 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]-quinolines, that may be used within the framework of the ADEP therapy (antibody directed enzyme prodrug therapy). The new prodrugs are characterised by a high difference in toxicity between the prodrug and underlying drug and by a very high efficacy of the drug. After splitting off of the glycosidic and/or acetal group on the phenolic hydroxy groups of the prodrugs, a spirocyclopropacyclohexadiene is formed which, being a highly toxic group, effects an alkylation of the DNA or RNA.Type: GrantFiled: May 2, 2001Date of Patent: May 8, 2007Inventors: Lutz F. Tietze, Tobias Herzig, Anja Fecher
-
Publication number: 20060194788Abstract: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R?)— or —O— and R? is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence.Type: ApplicationFiled: March 22, 2004Publication date: August 31, 2006Inventors: Eva Caroff, Matthias Steger, Oliver Valdenaire, Anja Fecher, Volker Breu, Kurt Hilpert, Heinz Fretz, Thomas Giller
-
Publication number: 20040033962Abstract: The chemotherapy of malignant tumours is greatly restricted by the generally slight differentiation of the available cytostatic agents between normal and malignant tissue. In order to achieve an improvement of the selectivity in cancer therapy, novel prodrugs have been developed from 6-hydroxy-2,3-dihydro-1H-indolene, 5-hydroxy-1,2-dihydro-3H-pyrrolo[3,2-e]indolene and 5-hydroxy-1,2-dihydro-3H-benzo[e]indolene as well as from 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]-quinolines, that may be used within the framework of the ADEP therapy (antibody directed enzyme prodrug therapy). The new prodrugs are characterised by a high difference in toxicity between the prodrug and underlying drug and by a very high efficacy of the drug. The high selectivity of the new prodrugs is probably attributed to the fact that, in the new prodrugs, a secondary halide is present in contrast to the prodrugs of a similar type previously produced by us.Type: ApplicationFiled: June 30, 2003Publication date: February 19, 2004Inventors: Lutz F. Tietze, Tobias Herzig, Anja Fecher